Article

pubs.acs.org/joc

Synthesis of Pyrazines from Rhodium-Catalyzed Reaction of
2H‑Azirines with N‑Sulfonyl 1,2,3-Triazoles
Taekyu Ryu, Yonghyeon Baek, and Phil Ho Lee*
National Creative Research Initiative Center for Catalytic Organic Reactions, Department of Chemistry, Kangwon National
University, Chuncheon 200-701, Republic of Korea
*S Supporting Information

ABSTRACT: An eﬃcient synthetic route to a wide range of trisubstituted pyrazines is developed from Rh-catalyzed reaction of
2H-azirines with N-sulfonyl-1,2,3-triazoles through the elimination of nitrogen molecule and arylsulﬁnic acid. The present
reaction proceeds through formation of in situ generated dihydropyrazines.

■ INTRODUCTION

Development of a new synthetic method for azaheterocyclic
compounds is highly signiﬁcant in the investigation for new
ingredients (API), and ﬁne
medicines, active pharmaceutical
chemicals.1
the most
representative privileged azaheterocyclic scaﬀolds, which show
cytostatic, antifungal, and antitumor properties and are broadly
present in ﬂavorings and alarm pheromones (Figure 1).2

In particular, pyrazine is one of

Figure 1. Bioactive compounds containing pyrazine moieties.

Accordingly, access to pyrazines from easily available starting
materials is highly required. In general, the preparation of novel
pyrazine scaﬀolds can be achieved by de novo synthesis from
suitable starting materials. To date, some of the most usual de
novo synthetic approaches described in the literature contain
condensation of α-oximido carbonyl compounds with allyl-
amines,3 1,4-addition of 1,2-diamines to 1,2-diaza-1,3-buta-
dienes,4 reductive condensation of α-nitro ketones with α-
amino ketones using electron transfer reagent,5 N−H insertion
of Boc-amino acid amides followed by acid-promoted cyclo-
dehydration,6 opening of epoxides with 1,2-amino alcohols and

Swern oxidation,7 Ru-catalyzed dehydrogenative coupling of β-
amino alcohols,8 and opening of 2H-azirines and dimerization.9
In addition, a wide range of pyrazines can be prepared by
functionalization of a preformed pyrazine nucleus or cyclo-
hexane derivatives having two nitrogen atoms at 1,4-position.10
However, some of these synthetic methods are restricted by
their low yields, rigorous conditions, diﬃculties of preparing
unsymmetrical substituted pyrazines, or
lack of substrate
variation.
<para sub=“ques”>
Over the last three years, the synthetic application of imino
carbenes derived from N-sulfonyl-1,2,3-triazoles has been a very
active area of research.11 In this regard, we have intensively
explored the utility of N-sulfonyl-1,2,3-triazoles as modular
building blocks for the preparation of a wide range of aza- and
carbo-heterocyclic compounds12 and C−H bond insertion of
azulene.13 In continuing studies, we envisaged that the Rh-
catalyzed reaction of 2H-azirines with N-sulfonyl-1,2,3-triazoles
would allow the formation of pyrazines. Herein we report an
eﬃcient method for the synthesis of a plethora of trisubstituted
pyrazines from Rh-catalyzed reaction of 2H-azirines with N-
sulfonyl-1,2,3-triazoles through the elimination of nitrogen
molecule and arylsulﬁnic acid (Scheme 1).14
</para>
Scheme 1. Synthesis of Pyrazines through Rhodium-
Catalyzed Reaction

Received:
Published:

January 6, 2015
January 25, 2015

© 2015 American Chemical Society

2376

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry

■ RESULTS AND DISCUSSION
<para sub=“opt”>
First, we commenced our studies with a variety of N-sulfonyl-4-
phenyl-1,2,3-triazoles (2) generated from Cu-catalyzed [3 + 2]
cycloaddition of phenylacetylenes with sulfonyl azides.15 4-
Methoxyphenylsulfonyl azide was the best 1,3-dipolar reagent
among several sulfonyl azides screened (methane-, isopropane-,
n-butane-, 4-triﬂuoromethylbenzene-, 4-methylbenzene-, and 4-
methoxybenzene-sulfonyl azide). Next, Rh-catalyzed reaction of
N-4-methoxybenzenesulfonyl-4-phenyl-1,2,3-triazole (2a) with
ethyl 3-(4-nitrophenyl)-2H-azirine-2-carboxylate (1a)16 was
investigated (Table 1). Ethyl acetate was the best solvent
</para>
Table 1. Reaction Optimizationa

Article
<para sub=“opt”>
of the stoichiometric ratio between starting materials 1a and 2a
is described in the Supporting Information.
</para>
<para sub="scope">
On the basis of the optimal reaction conditions, we next
explored the substrate scope as well as the functional group
compatibility in the reaction with ethyl 3-(4-nitrophenyl)-2H-
azirine-2-carboxylate (1a) (Scheme 2). Electronic variation of
</para>
Scheme 2. Rh-Catalyzed Synthesis of Pyrazines Using
Various Triazolesa

yield (%)b

solvent

entry
1
2
3
4
5
6
7
8
9
10
11
12
13

cat. (2.0 mol %)
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(OAc)4
Rh2(S-DOSP)4
Rh2(esp)2
-

5
-
-
-
-
-
-
-
53
56
-
-
-
-
aReactions were carried out with 1a (0.2 mmol) and 2a (1.5 equiv) in
solvent (1.0 mL, 0.2 M) at 120 °C for 16 h. bNMR yield using CH2Br2
as an internal standard. cIsolated yield of 3aa.

DCE
CHCl3
toluene
PhCl
n-hexane
cyclohexane
EtOAc
EtOAc
EtOAc
EtOAc
EtOAc
EtOAc
EtOAc

temp
(°C)
120
120
120
120
120
120
120
100
80
120
120
120
120

3aa

56
53
55
53
52
66
72
15
5
73 (70)c
66
64
-

4
16
17
-
-
-
-
-
14
15
-
12
12
-
<para sub=“opt”>
reaction media examined (dichloroethane,
among several
chloroform,
toluene, chlorobenzene, n-hexane, cyclohexane,
and ethyl acetate). A number of rhodium(II) catalysts were
tested to reveal that Rh2(Oct)4 (2.0 mol %) was the catalyst of
choice. The best result was obtained from a reaction of 1a (1.0
equiv, 0.2 mmol) with 2a (1.5 equiv) using Rh2(Oct)4 (2.0 mol
%) in ethyl acetate at 120 °C for 16 h, producing ethyl 3-(4-
nitrophenyl)-5-phenylpyrazine-2-carboxylate (3aa) in 70%
isolated yield (entry 10). When the present reaction was
conducted with Rh2(OAc)4 (2.0 mol %) at or below 100 °C,
dihydropyrazines 4 and 5 were produced (entries 8 and 9).
These results indicate that pyrazine 3aa is produced through
elimination of arylsulﬁnic acid from dihydropyrazines 4 and 5.
In addition, the present reaction did not proceed under thermal
conditions without using Rh catalyst (entry 13). Optimization
</para>

aReactions were carried out with 1a (0.2 mmol) and 2 (1.5 equiv) in
solvent (1.0 mL, 0.2 M) at 120 °C for 16 h. b2 (2.0 equiv) was used.
<para sub="scope">
substituents at the aryl ring of N-sulfonyl triazoles (2) did not
aﬀect the reaction eﬃciency. For example, N-4-methoxybenze-
nesulfonyl-4-aryl-1,2,3-triazoles (2) having electron-donating 3-
methyl, 4-methyl, 2-methoxy, and 3-methoxy groups on the
phenyl ring underwent the Rh-catalyzed reactions, aﬀording the
desired pyrazines (3ab, 3ac, 3ad, and 3ae) in good yields
ranging from 70% to 74%. The structure of 3ab was
unambiguously determined by X-ray crystallography (see the
Supporting Information).17 In addition,
the reactions of
substrates with electron-withdrawing 3-chloro, 4-chloro, 3-
bromo, and 4-bromo groups on the phenyl ring provided the
cyclization products (3af, 3ag, 3ah, and 3ai) in moderate to
good yields ranging from 51% to 81%. The tolerance of chloro
</para>
2377

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry

Article
<para sub="scope">
is especially meaningful, as

further
and bromo groups
transformations of
functional group are feasible. When a
substrate having electron-withdrawing triﬂuoromethyl group
was subjected to the Rh-catalyzed reaction, the product was
formed in 68% yield. Substrate (2k) having 2-naphthyl group
was also readily employed in the cyclization process. It was
noteworthy that triazole bearing 3-thiophenyl group was also
successfully applied to the current Rh-catalyzed reaction
conditions, producing 3al in 54% yield. When cyclohexenyl-
substituted triazole (2m) was reacted with 1a in the presence of
the rhodium catalyst, the desired pyrazine 3am was obtained in
51% yield. Triazole (2n) having a n-butyl group at 4-position
turned out
reaction
conditions, delivering the desired pyrazine 3an in 50% yield
without β-hydride elimination.

to be compatible with the optimal
</para>
<para sub="scope">
With the success of the above reactions, we next investigated
the eﬀects of a number of substituents of ethyl 3-(4-aryl)-2H-
azirine-2-carboxylate on cyclization (Scheme 3). Treatment of
</para>
Scheme 3. Rh-Catalyzed Synthesis of Pyrazines Using
Various 2H-Azirinesa

aReactions were carried out with 1a (0.2 mmol) and 2 (1.5 equiv) in
solvent (1.0 mL, 0.2 M) at 120 °C for 16 h. b2 (2.0 equiv) was used.
<para sub="scope">
triazole 2f with ethyl 3-(4-phenyl)-2H-azirine-2-carboxylate
(1b) aﬀorded ethyl 5-(3-chlorophenyl)-3-phenylpyrazine-2-
carboxylate (3bf) in 52% yield. Electronic modiﬁcation of
substituents on the aryl ring of 2H-azirine 1 did not largely
inﬂuence eﬃciency of the reaction. For instance, ethyl 3-(4-
chlorophenyl)-2H-azirine-2-carboxylate (1c) was converted to
the desired pyrazine 3cf in 73% yield. In addition, electron-
withdrawing 3- and 4-bromo groups on the aryl ring aﬀorded
the cyclization products (3df and 3ef) in good yields. 2H-
Azirine (1f) having 4-methoxycarbonyl group on the aryl ring
worked equally well in the reaction with triazole 2f to produce
the corresponding pyrazine 3ﬀ in 70% yield. When the 2H-
azirine (1g) bearing 2-naphthyl group was subjected to triazole
2f under
the optimal conditions, Rh-catalyzed reaction
smoothly took place to aﬀord trisubstituted pyrazine 3gf in
</para>
<para sub="scope">
58% yield. Unfortunately, 2H-azirines having electron-donating
substituents such as methyl and methoxy groups on the aryl
ring failed to prepare.
</para>
<para sub="scope">
A proposed reaction pathway for the formation of pyrazine
(3) from N-sulfonyl-1,2,3-triazole 2 and 2H-azirine 1 is shown
in Scheme 4. First, a ring−chain tautomerization of triazole 2
followed by treatment of a rhodium catalyst provides α-imino
rhodium carbenoid B along with evolution of nitrogen
molecule. Addition of 2H-azirine 1 to the carbene center of
B produces the rhodium-bound zwitterionic intermediate C.
Then, a ring-opening reaction through the release of an
electron pair from anionic rhodium of C provides dihydropyr-
azine 5 (pathway b). Finally, elimination of arylsulﬁnic acid
from 5 produces pyrazine 3. 6π-Electrocyclization (pathway a)
of 1,4-diazatriene D might be involved to the formation of
dihydropyrazine 5. Because regioisomeric pyrazine H and
pyrazine J are not observed from this reaction, an intra-
molecular hydrogen transfer (pathway d) and dimerization of
nitrile ylide dipole (pathway c) can be ruled out.14,18 In fact,
this postulation is supported by X-ray structure of pyrazine 3ab.
tert-butyl 3-methyl-2H-azirine-2-carboxylate was
In addition,
not reacted with triazole,
indicating that steric as well as
electronic eﬀects of substrate might be important
for the
formation of pyrazine.
</para>
■ CONCLUSION

In summary, we have developed an eﬃcient synthetic method
for a range of
trisubstituted pyrazines from Rh-catalyzed
reaction of 2H-azirines with N-sulfonyl-1,2,3-triazoles through
the elimination of nitrogen molecule and arylsulﬁnic acid. The
present
in situ
reaction proceeds
generated dihydropyrazines.

through formation of

■ EXPERIMENTAL SECTION
<para sub=“exp”>
General. Reactions were carried out in oven-dried glassware under
air atmosphere. Rh2(Oct)4, Rh2(OAc)4, Rh2(esp)2, Rh2(S-DOSP)4
were purchased and used as received. Commercial available reagents
were used without puriﬁcation. All reaction mixtures were stirred
magnetically and were monitored by thin-layer chromatography using
silica gel precoated glass plates, which were visualized with UV light
and then, developed using either iodine or a solution of anisaldehyde.
Flash column chromatography was carried out using silica gel (230−
400 mesh). 1H NMR (400 MHz), 13C{1H} NMR (100 MHz), and 19F
NMR (377 MHz) spectra were recorded on NMR spectrometer.
Deuterated chloroform was used as the solvent and chemical shift
values (δ) are reported in parts per million relative to the residual
signals of this solvent [δ 7.26 for 1H (chloroform-d), δ 2.05 for 1H
(acetone-d6), δ 77.2 for 13C{1H} (chloroform-d), and δ 29.84, 206.26
for 13C{1H} (acetone-d6)]. Infrared spectra were recorded on FT-IR
spectrometer as either a thin ﬁlm pressed between two sodium
chloride plates or as a solid suspended in a potassium bromide disk.
High resolution mass spectra (HRMS) were obtained by fast atom
bombardment (FAB) using a double focusing magnetic sector mass
spectrometer and electron impact (EI) ionization technique (magnetic
sector−electric sector double focusing mass analyzer). Melting points
were determined in open capillary tube.

Starting Materials of 2H-Azirines (1) and N-Sulfonyl-1,2,3-
triazoles (2).12b,16c Ethyl 3-(4-Nitrophenyl)-2H-azirine-2-carboxy-
late (1a). Yellow solid, melting point: 84−89 °C; 1H NMR (400 MHz,
CDCl3) δ 8.44 (d, J = 8.9 Hz, 2H), 8.10 (d, J = 8.8 Hz, 2H), 4.30−4.18
(m, 2H), 2.97 (s, 1H), 1.29 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 170.1, 158.6, 131.3, 130.4, 1280, 124.5, 61.7, 30.5,
14.2; IR (ﬁlm) 2984, 1727, 1528, 1465, 1346, 1316, 1202, 752, 685
cm−1; HRMS (FAB) [M + H]+ m/z calcd. for C11H11N2O4, 235.0719;
found, 235.0717.
</para>
2378

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry

Scheme 4. Proposed Mechanism

Article
<para sub=“exp”>
Ethyl 3-Phenyl-2H-azirine-2-carboxylate (1b). Yellow oil,

1H
NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.1 Hz, 2H), 7.67−7.57
(m, 3H), 4.26−4.18 (m, 2H), 2.85 (s, 1H), 1.28 (t, J = 7.1 Hz, 3H);
13C{1H} NMR (100 MHz, CDCl3) δ 171.7, 158.6, 133.9, 130.4, 129.3,
122.3, 61.3, 29.7, 14.2; IR (ﬁlm) 2982, 1729, 1579, 1465, 1451, 1334,
1199, 762, 689 cm−1; HRMS (FAB) [M + H]+ m/z calcd.
for
C11H12NO2, 190.0868; found, 190.0868.
Ethyl 3-(4-Chlorophenyl)-2H-azirine-2-carboxylate (1c). Yellow
solid, melting point: 57−62 °C; 1H NMR (400 MHz, CDCl3) δ 7.84
(d, J = 8.7 Hz, 2H), 7.57 (d, J = 8.6 Hz, 2H), 4.25−4.18 (m, 2H), 2.85
(s, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ
171.4, 158.0, 140.4, 131.6, 129.8, 120.8, 61.4, 29.8, 14.2; IR (ﬁlm)
2982, 1729, 1593, 1199, 835, 554 cm−1; HRMS (FAB) [M + H]+ m/z
calcd. for C11H11ClNO2, 224.0478; found, 224.0474.

Ethyl 3-(3-Bromophenyl)-2H-azirine-2-carboxylate (1d). Orange
oil, 1H NMR (400 MHz, CDCl3) δ 8.03 (t, J = 1.6 Hz, 1H), 7.84 (dt, J
= 7.7, 1.3 Hz, 1H), 7.77 (dq, J = 8.1, 1.0 Hz, 1H), 7.47 (t, J = 7.9 Hz,
1H), 4.26−4.17 (m, J = 7.1 Hz, 2H), 2.87 (s, 1H), 1.29 (t, J = 7.1 Hz,
3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.2, 158.1, 136.7, 132.9,
130.9, 128.8, 124.2, 123.2, 61.4, 30.0, 14.2; IR (ﬁlm) 2981, 1729, 1566,
1472, 1199, 787, 679, 578 cm−1; HRMS (FAB) [M + H]+ m/z calcd.
for C11H11BrNO2, 267.9973; found, 267.9975.
Ethyl 3-(4-Bromophenyl)-2H-azirine-2-carboxylate (1e). Orange
solid, melting point, 65−70 °C; 1H NMR (400 MHz, CDCl3) δ 7.75
(dd, J = 13.1, 8.8 Hz, 4H), 4.27−4.16 (m, 2H), 2.86 (s, 1H), 1.28 (t, J
= 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.4, 158.2,
132.8, 131.6, 129.0, 121.3, 61.4, 29.8, 14.2; IR (ﬁlm) 2981, 1728, 1588,
1481, 1445, 1334, 1199, 831, 702 cm−1; HRMS (FAB) [M + H]+ m/z
calcd. for C11H11BrNO2, 267.9973; found, 267.9972.

Ethyl 3-(4-(Methoxycarbonyl)phenyl)-2H-azirine-2-carboxylate
(1f). Yellow oil, 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.5 Hz,
2H), 7.97 (d, J = 8.6 Hz, 2H), 4.26−4.20 (m, 2H), 3.98 (s, 3H), 2.90
(s, 1H) 1.28 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ
171.3, 165.8, 153.7, 134.8, 130.4, 130.3, 126.1, 61.5, 52.7, 30.1, 14.3; IR
(ﬁlm) 2984, 2954, 1726, 1571, 1335, 1199, 863, 769, 693 cm−1;
HRMS (FAB) [M + H]+ m/z calcd. for C13H14NO4, 248.0923; found,
248.0920.
Ethyl 3-(Naphthalen-2-yl)-2H-azirine-2-carboxylate (1g). Yellow
oil, 1H NMR (400 MHz, CDCl3) δ 8.32 (S, 1H), 8.03−7.92 (m, 4H),
7.69−7.59 (m, 2H), 4.29−4.18 (m, 2H), 2.94 (s, 1H), 1.29 (t, J = 7.1
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.8, 158.6, 135.8,
133.0, 132.7, 129.4, 129.17, 129.2, 128.1, 127.4, 124.8, 119.6, 61.4,
29.9, 14.3; IR (ﬁlm) 2981, 1727, 1596, 1465, 1332, 1191, 863, 820,
750 cm−1; HRMS (FAB) [M + H]+ m/z calcd.
for C15H14NO2,
240.1025; found, 240.1024.
1-((4-Methoxyphenyl)sulfonyl)-4-phenyl-1H-1,2,3-triazole (2a).
White solid, melting point, 145−150 °C; 1H NMR (400 MHz,
CDCl3) δ 8.31 (s, 1H), 8.09 (d, J = 9.1 Hz, 2H), 7.84−7.82 (m, 2H),
7.46−7.41 (m, 2H), 7.39−7.35 (m, 1H), 7.04 (d, J = 9.1 Hz, 2H), 3.89
(s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.4, 147.3, 131.2,
129.1, 129.0, 128.9, 126.9, 126.1, 118.8, 115.1, 56.0; IR (ﬁlm) 3090,
1590, 1268, 1166, 839, 768, 674 cm−1; HRMS (EI) m/z calcd. for
C15H13N3O3S, 315.0678; found, 315.0676.
1-((4-Methoxyphenyl)sulfonyl)-4-(p-tolyl)-1H-1,2,3-triazole (2b).
White solid, melting point, 152−157 °C; 1H NMR (400 MHz,
CDCl3) δ 8.26 (s, 1H), 8.08 (d, J = 9.1 Hz, 2H), 7.71 (d, J = 8.2 Hz,
2H), 7.24 (d, J = 7.9 Hz, 2H), 7.04 (d, J = 9.1 Hz, 2H), 3.89 (s, 3H),
2.38 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.4, 147.4, 139.1,
131.2, 129.7, 127.1, 126.1, 126.0, 118.4, 115.1, 56.0, 21.4; IR (ﬁlm)
</para>
2379

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry
<para sub=“exp”>
3050, 1590, 1263, 1169, 1002, 980, 820, 770, 675 cm−1; HRMS (EI)
m/z calcd. for C16H15N3O3S, 329.0834; found, 329.0833.
1-((4-Methoxyphenyl)sulfonyl)-4-(m-tolyl)-1H-1,2,3-triazole (2c).
White solid, melting point, 85−90 °C;
1H NMR (400 MHz,
CDCl3) δ 8.29 (s, 1H), 8.08 (d, J = 9.1 Hz, 2H), 7.67 (s, 1H), 7.61
(d, J = 7.7 Hz, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H),
7.04 (d, J = 9.1 Hz, 2H), 3.89 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3) δ 165.4, 147.4, 138.8, 131.2, 129.8, 128.9, 128.8, 127.0, 126.7,
123.2, 118.8, 115.1, 56.0, 21.4; IR (ﬁlm) 2916, 1592, 1268, 1197, 1166,
1091, 1006, 836, 785, 680 cm−1; HRMS (EI) m/z calcd.
for
C16H15N3O3S, 329.0834; found, 329.0835.
4-(2-Methoxyphenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tri-
azole (2d). White solid, melting point, 110−115 °;, 1H NMR (400
MHz, CDCl3) δ 8.57 (s, 1H), 8.32 (dd, J = 7.8, J = 1.7 Hz, 1H), 8.09
(d, J = 9.0 Hz, 2H), 7.34 (td, J = 7.8, J = 1.7 Hz, 1H), 7.09−7.00 (m,
4H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.2, 156.0, 142.7, 131.1,
130.0, 128.0, 127.4, 122.0, 121.0, 117.8, 115.0, 110.8, 56.0, 55.5; IR
(ﬁlm): 3076, 1592, 1267, 1022, 835, 755, 678 cm−1; HRMS (EI) m/z
calcd. for C16H15N3O4S, 345.0783; found, 345.0785.
4-(3-Methoxyphenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tri-
azole (2e). White solid, melting point, 76−81 °C; 1H NMR (400
MHz, CDCl3) δ 8.30 (s, 1H), 8.09 (d, J = 9.0 Hz, 2H), 7.42−7.31 (m,
3H), 7.04 (d, J = 9.0 Hz, 2H), 6.92 (dt, J = 7.4, 2.2 Hz, 1H), 3.89 (s,
3H), 3.86 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.4, 160.1,
147.2, 131.2, 130.2, 130.1, 126.9, 119.0, 118.4, 115.1, 111.1, 77.3, 56.0,
55.4; IR (ﬁlm) 2943, 1592, 1269, 1044, 1024, 835, 783, 678 cm−1;
HRMS (EI) m/z calcd. for C16H15N3O4S, 345.0783; found, 345.0786.
4-(3-Chlorophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tria-
zole (2f). White solid, melting point, 132−137 °C; 1H NMR (400
MHz, CDCl3) δ 8.32 (s, 1H), 8.09 (d, J = 9.1 Hz, 2H), 7.84−7.83 (m,
1H), 7.71 (dt, J = 7.0, 1.7, Hz, 1H), 7.39−7.33 (m, 2H), 7.05 (d, J =
9.1 Hz, 2H), 3.89 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.5,
146.0, 135.0, 131.3, 130.8, 130.3, 129.1, 126.8, 126.1, 124.1, 119.3,
115.2, 56.0; IR (ﬁlm) 3143, 1292, 1269, 1022, 963, 767, 676, 586
cm−1; HRMS (EI) m/z calcd. for C15H12ClN3O3S, 349.0288; found,
349.0286.
4-(4-Chlorophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tria-
zole (2g). White solid, melting point, 129−134 °C; 1H NMR (400
MHz, CDCl3) δ 8.30 (s, 1H), 8.09 (d, J = 9.1 Hz, 2H), 7.77 (d, J = 8.6
Hz, 2H), 7.41 (d, J = 8.6 Hz, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.89 (s,
3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.5, 146.2, 134.9, 131.3,
129.3, 127.5, 127.3, 126.8, 118.9, 115.2, 56.0; IR (ﬁlm) 3095, 1591,
1267, 1022, 836, 781, 679, 591 cm−1; HRMS (EI) m/z calcd. for
C15H12ClN3O3S, 349.0288; found, 349.0284.
4-(3-Bromophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tria-
zole (2h). White solid, melting point, 103−108 °C; 1H NMR (400
MHz, CDCl3) δ 8.32 (s, 1H), 8.09 (d, J = 9.1 Hz, 2H), 7.99 (t, J = 1.7
Hz, 1H), 7.78−7.75 (m, 1H), 7.50 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.31
(t, J = 7.9 Hz, 1H), 7.05 (d, J = 9.1 Hz, 2H), 3.90 (s, 3H); 13C{1H}
NMR (100 MHz, CDCl3) δ 165.6, 145.9, 132.1, 131.4, 131.1, 130.7,
129.1, 126.8, 124.7, 123.2, 119.4, 115.3, 56.1; IR (ﬁlm) 2944, 1592,
1269, 1024, 835, 784, 676, 589 cm−1; HRMS (EI) m/z calcd. for
C15H12BrN3O3S, 392.9783; found, 392.9783.
4-(4-Bromophenyl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-tria-
zole (2i). White solid, melting point, 155−160 °C; 1H NMR (400
MHz, acetone-d6) δ 9.07 (s, 1H), 8.15 (d, J = 9.0 Hz, 2H), 7.94 (d, J =
8.4 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 9.0 Hz, 2H), 3.96 (s,
3H); 13C{1H} NMR (100 MHz, acetone-d6) δ 166.6, 146.9, 132.9,
132.0, 129.5, 128.6, 127.7, 123.2, 121.4, 116.3, 56.6; IR (ﬁlm) 2976,
1591, 1267, 1197, 1019, 837, 786, 679, 593 cm−1; HRMS (EI) m/z
calcd. for C15H12BrN3O3S, 392.9783; found, 392.9784.
1-((4-Methoxyphenyl)sulfonyl)-4-(4-(triﬂuoromethyl)phenyl)-1H-
1,2,3-triazole (2j). White solid, melting point, 133−138 °C; 1H NMR
(400 MHz, CDCl3) δ 8.39 (s, 1H), 8.10 (d, J = 9.1 Hz, 2H), 7.96 (d, J
= 8.0 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.06 (d, J = 9.1 Hz, 2H), 3.90
(s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.6, 145.8, 131.4,
130.9 (q, J = 32.5 Hz), 126.2, 126.02, 126.01 (q, J = 4.2 Hz), 125.98,
123.9 (q, J = 272.2 Hz), 119.7, 115.2, 56.0; 19F NMR (377 MHz,
CDCl3) δ −62.73; IR (ﬁlm) 3106, 1596, 1394, 1326, 1270, 1164,
</para>
Article
<para sub=“exp”>
1024, 838, 829, 679 cm−1; HRMS (EI) m/z calcd. for C16H12F3N3O3S,
383.0551; found, 383.0549.
1-((4-Methoxyphenyl)sulfonyl)-4-(naphthalen-2-yl)-1H-1,2,3-tria-
zole (2k). White solid, melting point, 130−135 °C; 1H NMR (400
MHz, CDCl3) δ 8.42 (s, 1H), 8.37 (s, 1H), 8.11 (d, J = 9.1 Hz, 2H),
7.92−7.84 (m, 4H), 7.54−7.49 (m, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.90
(s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.4, 147.3, 133.5,
133.4, 131.3, 128.8, 128.3, 127.8, 127.0, 126.7, 126.67, 126.2, 125.3,
123.6, 125.3, 123.6, 119.1, 115.1, 56.0; IR (ﬁlm) 3144, 1592, 1268,
1019, 804, 751, 676 cm−1; HRMS (EI) m/z calcd. for C19H15N3O3S,
365.0834; found, 365.0832.
1-((4-Methoxyphenyl)sulfonyl)-4-(thiophen-3-yl)-1H-1,2,3-tria-
zole (2l). White solid, melting point, 150−155 °C; 1H NMR (400
MHz, CDCl3) δ 8.20 (s, 1H), 8.08−8.05 (m, 2H), 7.76−7.75 (m, 1H),
7.43−7.39 (m, 2H), 7.05−7.02 (m, 2H), 3.89 (s, 3H); 13C{1H} NMR
(100 MHz, CDCl3) δ 165.4, 143.4, 131.2, 130.1, 126.9, 126.8, 125.7,
122.7, 118.5, 115.1, 56.0; IR (ﬁlm) 3098, 1590, 1268, 1006, 837, 785,
676 cm−1; HRMS (EI) m/z calcd. for C13H11N3O3S2, 321.0242; found,
321.0242.
4-(Cyclohex-1-en-1-yl)-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-
triazole (2m). White solid, melting point, 96−100 °C; 1H NMR (400
MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz 2H), 7.89 (s, 1H), 7.01 (d, J = 9.1
Hz, 2H), 6.67−6.64 (m, 1H), 3.88 (s, 3H), 2.33−2.29 (m, 2H), 2.22−
2.17 (m, 2H), 1.78−1.72 (m, 2H), 1.68−1.62 (m, 2H); 13C{1H} NMR
(100 MHz, CDCl3) δ 165.2, 148.9, 131.0, 127.5, 127.2, 125.8, 117.3,
115.0, 56.0, 26.2, 25.3, 22.2, 22.0; IR (ﬁlm) 2931, 2858, 1592, 1268,
1020, 966, 835, 804, 676 cm−1; HRMS (EI) m/z calcd.
for
C15H17N3O3S, 319.0991; found, 319.0992.
4-Butyl-1-((4-methoxyphenyl)sulfonyl)-1H-1,2,3-triazole (2n).
White solid, melting point, 75−80 °C;
1H NMR (400 MHz,
CDCl3) δ 8.04 (d, J = 9.1 Hz, 2H), 7.83 (s, 1H), 7.02 (d, J = 9.1
Hz, 2H), 3.89 (s, 3H), 2.71 (t, J = 15.4 Hz, 2H), 1.68−1.60 (m, 2H),
1.39−1.34 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 165.2, 148.2, 131.0, 127.2, 120.2, 115.0, 55.9, 31.0,
25.1, 22.2, 13.7; IR (ﬁlm) 2957, 2932, 1593, 1462, 1269, 1013, 835,
715, 676 cm−1; HRMS (EI) m/z calcd. for C13H17N3O3S, 295.0991;
found, 295.0993.

General Procedure for the Preparation of Pyrazines (3). To a
screw-top V-vial were added 2H-azirine derivatives (2a, 0.2 mmol),
triazole derivatives (1a, 0.3 mmol), and Rh2(Oct)4 (3.1 mg, 0.004
mmol) in EtOAc (1.0 mL). The resulting mixture was stirred at 120
°C for 16 h. After Celite ﬁltration and evaporation of the solvents in
vacuo, the crude product was puriﬁed by column chromatography on
silica gel (EtOAc:Hx = 1:5) to yield 3aa (48.9 mg, 70%) as a white
solid.

Ethyl 3-(4-Nitrophenyl)-5-phenylpyrazine-2-carboxylate (3aa).
Yield 48.9 mg (70%), Rf = 0.26 (EtOAc:Hx = 1:5); White solid,
melting point, 137−142 °C; 1H NMR (400 MHz, CDCl3) δ 9.12 (s,
1H), 8.37 (d, J = 8.9 Hz, 2H), 8.16−8.14 (m, 2H), 7.87 (d, J = 8.9 Hz,
2H), 7.58−7.55 (m, 3H), 4.36 (q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz,
3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.6, 153.0, 151.3, 148.4,
144.0, 141.8, 139.8, 134.9, 131.1, 129.9, 129.3, 127.5, 123.5, 62.5, 13.9;
IR (ﬁlm) 3059, 2978, 1730, 1520, 1437, 1347, 1138, 1012, 853 cm−1;
HRMS (EI) m/z calcd for C19H15N3O4, 349.1063; found, 349.1060.
Ethyl 3-(4-Nitrophenyl)-5-(p-tolyl)pyrazine-2-carboxylate (3ab).
Yield 51.6 mg (71%), Rf = 0.2 (EtOAc:Hx = 1:5); white solid, melting
point, 131−136 °C; 1H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 8.36
(d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.2 Hz, 2H), 7.86 (d, J = 8.9 Hz, 2H),
7.36 (d, J = 8.0 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.27 (t,
J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.6, 153.1,
151.4, 148.3, 144.2, 141.7, 141.3, 139.5, 132.1, 130.1, 129.9, 127.4,
123.5, 62.5, 21.5, 13.9; IR (ﬁlm) 3056, 2982, 1728, 1521, 1443, 1348,
1139, 1014, 853 cm−1; HRMS (EI) m/z calcd for C20H17N3O4,
363.1219; found, 363.1216.

Ethyl 3-(4-Nitrophenyl)-5-(m-tolyl)pyrazine-2-carboxylate (3ac).
Yield 53.8 mg (74%), Rf = 0.24 (EtOAc:Hx = 1:5); white solid,
melting point, 105−110 °C; 1H NMR (400 MHz, CDCl3) δ 9.10 (s,
1H), 8.37 (d, J = 8.9 Hz, 2H), 7.95−7.92 (m, 2H), 7.87 (d, J = 8.9 Hz,
2H), 7.45 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 4.36 (q, J = 7.1
Hz, 2H), 2.48 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
</para>
2380

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry

Article
<para sub=“exp”>
MHz, CDCl3) δ 165.6, 153.2, 151.4, 148.4, 144.1, 141.6, 139.9, 139.2,
134.8, 132.0, 129.9, 129.2, 128.1, 124.7, 123.5, 62.5, 21.6, 13.9; IR
(ﬁlm) 3053, 2982, 1731, 1521, 1443, 1348, 1137, 1014, 853 cm−1;
HRMS (EI) m/z calcd for C20H17N3O4, 363.1219; found, 363.1217.
Ethyl 5-(2-Methoxyphenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ad). Yield 53.2 mg (70%), Rf = 0.14 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 135−140 °C; 1H NMR (400 MHz,
CDCl3) δ 9.33 (s, 1H), 8.35 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.7, 1.8
Hz, 1H), 7.85 (d, J = 8.9 Hz, 2H), 7.50 (ddd, J = 8.3, 7.4, 1.7 Hz, 1H),
7.13 (td, J = 7.5, 0.9 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 4.36 (q, J = 7.1
Hz, 2H), 3.95 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 165.7, 157.7, 152.4, 151.3, 148.2, 144.4, 144.3, 140.7,
132.3, 131.5, 129.9, 124.3, 123.5, 121.5, 111.6, 62.4, 55.7, 14.0; IR
(ﬁlm) 3078, 2980, 1731, 1520, 1436, 1347, 1139, 1019, 853 cm−1;
HRMS (EI) m/z calcd for C20H17N3O5, 379.1168; found, 379.1169.
Ethyl 5-(3-Methoxyphenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ae). Yield 53.0 mg (70%), Rf = 0.2 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 155−160 °C; 1H NMR (400 MHz,
CDCl3) δ 9.10 (s, 1H), 8.36 (d, J = 8.8 Hz, 2H), 7.87 (d, J = 8.8 Hz,
2H), 7.71−7.69 (m, 2H), 7.47 (t, J = 8.2 Hz, 1H), 7.10−7.08 (m, 1H),
4.36 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H);
13C{1H} NMR (100 MHz, CDCl3) δ 165.5, 160.4, 152.8, 151.3, 148.4,
144.0, 141.9, 139.9, 136.2, 130.4, 129.9, 123.5, 119.8, 116.6, 113.1,
62.5, 55.5, 13.9; IR (ﬁlm) 3075, 2938, 1728, 1520, 1459, 1348, 1136,
1028, 853 cm−1; HRMS (EI) m/z calcd for C20H17N3O5, 379.1168;
found, 379.1165.

Ethyl 5-(3-Chlorophenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3af). Yield 57.5 mg (75%), Rf = 0.23 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 130−135 °C; 1H NMR (400 MHz,
CDCl3) δ 9.10 (s, 1H), 8.37 (d, J = 8.9 Hz, 2H), 8.16−8.15 (m, 1H),
8.03−8.00 (m, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.54−7.48 (m, 2H), 4.37
(q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 165.4, 151.6, 151.4, 148.5, 143.6, 142.5, 139.7, 136.6,
135.5, 131.1, 130.6, 129.9, 127.6, 125.5, 123.6, 62.6, 13.9; IR (ﬁlm)
3053, 2986, 1731, 1525, 1421, 1349, 1143, 1014, 854 cm−1; HRMS
(EI) m/z calcd for C19H14ClN3O4, 383.0673; found, 383.0674.

Ethyl 5-(4-Chlorophenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ag). Yield 39.1 mg (51%), Rf = 0.23 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 178−183 °C; 1H NMR (400 MHz,
CDCl3) δ 9.09 (s, 1H), 8.37 (d, J = 8.8 Hz, 2H), 8.10 (d, J = 8.7 Hz,
2H), 7.86 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.7 Hz, 2H), 4.36 (q, J = 7.1
Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3)
δ 165.4, 151.8, 151.4, 148.5, 143.8, 142.1, 139.5, 137.6, 133.3, 129.9,
129.6, 128.7, 123.6, 62.6, 13.9; IR (ﬁlm) 3058, 2984, 1721, 1519, 1442,
1349, 1140, 1010, 853, 516 cm−1; HRMS (EI) m/z calcd for
C19H14ClN3O4, 383.0673; found, 383.0675.

Ethyl 5-(3-Bromophenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ah). Yield 69.2 mg (81%), Rf = 0.2 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 150−155 °C; 1H NMR (400 MHz,
CDCl3) δ 9.09 (s, 1H), 8.38 (d, J = 8.8 Hz, 2H), 8.30 (t, J = 1.8 Hz,
1H), 8.06 (ddd, J = 7.9, 1.5, 1.0 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.68
(ddd, J = 8.0, 1.9, 0.9 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 4.37 (q, J = 7.1
Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3)
δ 165.4, 151.5, 151.4, 148.5, 143.6, 142.5, 139.7, 136.8, 134.1, 130.8,
130.5, 129.9, 125.9, 123.6, 62.6, 13.9; IR (ﬁlm) 3068, 2983, 1731,
1520, 1443, 1348, 1141, 1065, 853 cm−1; HRMS (EI) m/z calcd for
C19H14BrN3O4, 427.0168; found, 427.0166.

Ethyl 5-(4-Bromophenyl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ai). Yield 45.3 mg (53%), Rf = 0.2 (EtOAc:Hx = 1:5); pale
yellow solid, melting point, 192−197 °C; 1H NMR (400 MHz,
CDCl3) δ 9.09 (s, 1H), 8.37 (d, J = 8.9 Hz, 2H), 8.03 (d, J = 8.7 Hz,
2H), 7.86 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 4.36 (q, J = 7.1
Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3)
δ 165.4, 151.9, 151.4, 148.5, 143.7, 142.1, 139.4, 133.7, 132.6, 129.9,
128.9, 126.1, 123.6, 62.6, 13.9; IR (ﬁlm) 3058, 2983, 1720, 1520, 1441,
1348, 1139, 1006, 853 cm−1; HRMS (EI) m/z calcd for
C19H14BrN3O4, 427.0168; found, 427.0164.

Ethyl 3-(4-Nitrophenyl)-5-(4-(triﬂuoromethyl)phenyl)pyrazine-2-
carboxylate (3aj). Yield 56.5 mg (68%), Rf = 0.23 (EtOAc:Hx =
1:5); pale yellow solid, melting point, 165−170 °C; 1H NMR (400

MHz, CDCl3) δ 9.16 (s, 1H), 8.38 (d, J = 8.9 Hz, 2H), 8.27 (d, J = 8.1
Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.2 Hz, 2H), 4.38 (q, J
= 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz,
CDCl3) δ 165.4, 151.5, 151.4, 148.5, 143.5, 142.8, 139.9, 138.2, 132.8
(q, J = 32.8 Hz), 129.9, 127.9, 126.2 (q, J = 3.7 Hz), 123.8 (q, J =
272.9 Hz), 123.6, 62.7, 13.9; 19F NMR (377 MHz, CDCl3) δ −62.89;
IR (ﬁlm) 3054, 2987, 1724, 1517, 1446, 1325, 1139, 1112, 1012, 854
cm−1; HRMS (EI) m/z calcd for C20H14F3N3O4, 417.0936; found,
417.0936.

Ethyl 5-(Naphthalen-2-yl)-3-(4-nitrophenyl)pyrazine-2-carboxy-
late (3ak). Yield 39.9 mg (50%), Rf = 0.2 (EtOAc:Hx = 1:5); white
solid, melting point, 165−170 °C; 1H NMR (400 MHz, CDCl3) δ
9.27 (s, 1H), 8.65 (d, J = 1.1 Hz, 1H), 8.39 (d, J = 8.8 Hz, 2H), 8.25
(dd, J = 8.6, 1.8 Hz, 1H), 8.03−8.00 (m, 2H), 7.93−7.89 (m, 3H),
7.62−7.56 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H);
13C{1H} NMR (100 MHz, CDCl3) δ 165.6, 153.0, 151.5, 148.4, 144.1,
141.6, 140.0, 134.5, 133.3, 132.1, 130.0, 129.2, 129.0, 127.9, 127.88,
127.0, 123.9, 123.6, 62.5, 14.0; IR (ﬁlm) 3057, 2982, 1730, 1520, 1434,
1348, 1138, 1013, 853 cm−1; HRMS (EI) m/z calcd for C23H17N3O4,
399.1219; found, 399.1218.

Ethyl 3-(4-Nitrophenyl)-5-(thiophen-3-yl)pyrazine-2-carboxylate
(3al). Yield 38.4 mg (54%), Rf = 0.23 (EtOAc:Hx = 1:5); pale yellow
solid, melting point, 171−175 °C; 1H NMR (400 MHz, CDCl3) δ
8.99 (s, 1H), 8.36 (d, J = 8.8 Hz, 2H), 8.18 (dd, J = 3.0, 1.2 Hz, 1H),
7.84 (d, J = 8.8 Hz, 2H), 7.79 (dd, J = 5.1, 1.2 Hz, 1H), 7.50 (dd, J =
5.1, 3.0 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H);
13C{1H} NMR (100 MHz, CDCl3) δ 165.4, 151.7, 149.2, 148.3, 144.0,
141.1, 139.6, 137.8, 129.9, 127.6, 127.3, 126.0, 123.5, 62.5, 13.9; IR
(ﬁlm) 3073, 2984, 1710, 1521, 1460, 1351, 1140, 1015, 853 cm−1;
HRMS (EI) m/z calcd for C17H13N3O4S, 355.0627; found, 355.0626.
Ethyl 5-(Cyclohex-1-en-1-yl)-3-(4-nitrophenyl)pyrazine-2-carbox-
ylate (3am). Yield 36 mg (51%), Rf = 0.31 (EtOAc:Hx = 1:5); yellow
oil; 1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.33 (d, J = 8.9 Hz,
2H), 7.79 (d, J = 8.9 Hz, 2H), 7.03−7.00 (m, 1H), 4.33 (q, J = 7.1 Hz,
2H), 2.60−2.57 (m, 2H), 2.37−2.33 (m, 2H), 1.86−1.80 (m, 2H),
1.75−1.69 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 165.7, 154.4, 150.7, 148.2, 144.4, 140.6, 138.7, 134.5,
134.0, 129.9, 123.4, 62.3, 26.3, 25.2, 22.4, 21.7, 13.9; IR (ﬁlm) 3051,
2931, 1730, 1520, 1444, 1348, 1135, 1013, 852 cm−1; HRMS (EI) m/z
calcd for C19H19N3O4, 353.1376; found, 353.1373.

Ethyl 5-Butyl-3-(4-nitrophenyl)pyrazine-2-carboxylate (3an).
Yield 32.9 mg (50%), Rf = 0.36 (EtOAc:Hx = 1:5); yellow oil; 1H
NMR (400 MHz, CDCl3) δ 8.56 (s, 1H), 8.34 (d, J = 8.8 Hz, 2H),
7.77 (d, J = 8.8 Hz, 2H), 4.33 (q, J = 7.1 Hz, 2H), 2.97−2.93 (m, 2H),
1.83−1.75 (m, 2H), 1.49−1.39 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H), 0.97
(t, J = 7.3 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 165.7, 159.5,
151.2, 148.3, 144.1, 142.6, 141.4, 129.8, 123.5, 62.4, 35.3, 31.3, 22.4,
13.9, 13.8; IR (ﬁlm) 3046, 2958, 1733, 1521, 1445, 1348, 1129, 1014,
853 cm−1; HRMS (EI) m/z calcd for C17H19N3O4, 329.1376; found,
329.1377.

Ethyl 5-(3-Chlorophenyl)-3-phenylpyrazine-2-carboxylate (3bf).
Yield 35.2 mg (52%), Rf = 0.14 (EtOAc:Hx = 1:10); yellow oil; 1H
NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 8.18−8.17 (m, 1H), 8.03−
8.00 (m, 1H), 7.74−7.70 (m, 2H), 7.53−7.45 (m, 5H), 4.32 (q, J = 7.1
Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3)
δ 166.4, 153.0, 151.1, 142.9, 138.5, 137.3, 137.2, 135.4, 130.6, 130.4,
129.7, 128.8, 128.5, 127.5, 125.4, 62.2, 13.8; IR (ﬁlm) 3064, 2981,
1732, 1421, 1139, 1064, 1022, 838 cm−1; HRMS (EI) m/z calcd for
C19H15ClN2O2, 338.0822; found, 338.0824.

Ethyl 5-(3-chlorophenyl)-3-(4-chlorophenyl)pyrazine-2-carboxy-
late (3cf). Yield 54.5 mg (73%), Rf = 0.17 (EtOAc:Hx = 1:5); yellow
oil; 1H NMR (400 MHz, CDCl3) δ 9.01 (s, 1H), 8.15−8.14 (m, 1H),
8.01−7.99 (m, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.52−7.46 (m, 4H), 4.35
(q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3) δ 166.1, 151.9, 151.2, 142.6, 138.7, 137.0, 136.1, 135.7,
135.4, 130.8, 130.4, 130.2, 128.8, 127.5, 125.4, 62.4, 13.9; IR (ﬁlm)
3068, 2981, 1733, 1444, 1139, 1067, 1013, 844 cm−1; HRMS (EI) m/z
calcd for C19H14Cl2N2O2, 372.0432; found, 372.0431.

Ethyl 3-(3-Bromophenyl)-5-(3-chlorophenyl)pyrazine-2-carboxy-
late (3df). Yield 59.1 mg (71%), Rf = 0.37 (EtOAc:Hx = 1:5); yellow
</para>
2381

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

The Journal of Organic Chemistry
<para sub=“exp”>
solid, melting point, 55−59 °C; 1H NMR (400 MHz, CDCl3) δ 9.02
(s, 1H), 8.15−8.14 (m, 1H), 8.01 (dt, J = 6.7, 1.9 Hz, 1H), 7.86 (t, J =
1.8 Hz, 1H), 7.65−7.61 (m, 2H), 7.52−7.46 (m, 2H), 7.37 (t, J = 7.9
Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H); 13C{1H}
NMR (100 MHz, CDCl3) δ 165.9, 151.5, 151.3, 142.8, 139.2, 139.0,
137.0, 135.4, 132.7, 131.8, 130.8, 130.5, 130.0, 127.5, 127.4, 125.5,
122.5, 62.4, 13.9; IR (ﬁlm) 3066, 2980, 1732, 1422, 1141, 1068, 1139,
1012, 841 cm−1; HRMS (EI) m/z calcd for C19H14BrClN2O2,
415.9927; found, 415.9926.

Ethyl 3-(4-Bromophenyl)-5-(3-chlorophenyl)pyrazine-2-carboxy-
late (3ef). Yield 60.1 mg (72%), Rf = 0.18 (EtOAc:Hx = 1:5); white
solid, melting point, 82−87 °C; 1H NMR (400 MHz, CDCl3) δ 9.01
(s, 1H), 8.15−8.14 (m, 1H), 8.01−7.99 (m, 1H), 7.65 (d, J = 8.6 Hz,
2H), 7.59 (d, J = 8.6 Hz, 2H), 7.52−7.46 (m, 2H), 4.35 (q, J = 7.1 Hz,
2H), 1.26 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ
166.1, 152.0, 151.2, 142.5, 138.8, 137.0, 136.2, 135.4, 131.7, 130.8,
130.44, 130.41, 127.5, 125.4, 124.5, 62.4, 13.9; IR (ﬁlm) 3067, 2981,
1732, 1443, 1140, 1069, 1034, 1009, 842 cm−1; HRMS (EI) m/z calcd
for C19H14BrClN2O2, 415.9927; found, 415.9928.

Ethyl 5-(3-Chlorophenyl)-3-(4-(methoxycarbonyl)phenyl)-
pyrazine-2-carboxylate (3ﬀ). Yield 55.6 mg (70%), Rf = 0.29
(EtOAc:Hx = 1:5); white solid, melting point, 142−147 °C; 1H
NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H),
8.16−8.15 (m, 1H), 8.03−8.00 (m, 1H), 7.78 (d, J = 8.6 Hz, 2H),
7.52−7.47 (m, 2H), 4.33 (q, J = 7.2 Hz, 2H), 3.97 (s, 3H), 1.21 (t, J =
7.2 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 166.6, 165.9, 152.2,
151.3, 142.8, 141.6, 139.1, 137.0, 135.5, 131.1, 130.9, 130.5, 129.7,
128.9, 127.6, 125.4, 62.4, 52.4, 13.8; IR (ﬁlm) 3067, 2983, 1725, 1435,
1279, 1140, 1067, 1016, 862 cm−1; HRMS (EI) m/z calcd for
C21H17ClN2O4, 396.0877; found, 396.0878.

Ethyl 5-(3-Chlorophenyl)-3-(naphthalen-2-yl)pyrazine-2-carbox-
ylate (3gf). Yield 45.1 mg (58%), Rf = 0.26 (EtOAc:Hx = 1:5); yellow
oil; 1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H), 8.22−8.20 (m, 2H),
8.06−8.03 (m, 1H), 7.99−7.91 (m, 3H), 7.83 (dd, J = 8.5, 1.8 Hz,
1H), 7.59−7.53 (m, 2H), 7.52−7.47 (m, 2H), 4.32 (q, J = 7.1 Hz,
2H), 1.15 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ
166.5, 152.9, 151.2, 143.1, 138.5, 137.3, 135.4, 134.6, 133.8, 133.0,
130.7, 130.4, 128.8, 128.7, 128.3, 127.8, 127.6, 127.2, 126.7, 125.9,
125.5, 62.3, 13.9; IR (ﬁlm) 3061, 2980, 1731, 1445, 1139, 1068, 1014,
861 cm−1; HRMS (EI) m/z calcd for C23H17ClN2O2, 388.0979; found,
388.0977.

Ethyl 3-(4-Nitrophenyl)-5-phenyl-1-tosyl-1,4-dihydropyrazine-2-
carboxylate (4). Rf = 0.35 (EtOAc:Hx = 1:2); yellow solid, melting
point, 224−227 °C; 1H NMR (400 MHz, acetone-d6) δ 11.13 (s, 1H),
8.26 (d, J = 9.0 Hz, 2H), 7.86 (d, J = 9.0 Hz, 2H), 7.83−7.79 (m, 3H),
7.42 (d, J = 8.3 Hz, 2H), 7.36−7.32 (m, 2H), 7.29−7.25 (m, 1H), 7.17
(d, J = 8.0 Hz, 2H), 3.92 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 1.11 (t, J =
7.1 Hz, 3H); 13C{1H} NMR (100 MHz, acetone-d6) δ 164.6, 148.1,
144.0, 139.0, 137.8, 133.1, 131.9, 131.7, 131.0, 129.8, 129.0, 128.4,
128.2, 128.1, 123.7, 119.5, 113.0, 60.7, 21.4, 14.2; IR (ﬁlm) 3280,
3064, 2982, 1685, 1516, 1400, 1343, 1256, 1161 cm−1; HRMS (EI) m/
z calcd for C26H23N3O6S, 505.1308; found, 505.1310.

Ethyl 3-(4-Nitrophenyl)-5-phenyl-1-tosyl-1,2-dihydropyrazine-2-
carboxylate (5). Rf = 0.34 (EtOAc:Hx = 1:5); yellow oil; 1H NMR
(400 MHz, 400 MHz, CDCl3) δ 8.29 (d, J = 9.0 Hz, 2H), 8.10 (d, J =
9.0 Hz, 2H), 7.76−7.74 (m, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.43−7.39
(m, 2H), 7.37−7.32 (m, 1H), 7.14 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 1.4
Hz, 1H), 6.05 (d, J = 1.4 Hz, 1H), 4.18−3.99 (m, 2H), 2.33 (s, 3H),
1.11 (t, J = 7.1 Hz, 3H) ; 13C{1H} NMR (100 MHz, CDCl3) δ 166.0,
148.8, 145.1, 145.0, 141.2, 135.5, 135.2, 135.0, 129.9, 128.7, 128.5,
128.3, 126.6, 124.9, 123.7, 111.4, 62.8, 52.8, 21.6, 13.9; IR (ﬁlm) 3081,
2981, 1733, 1596, 1521, 1346, 1317, 1169 cm−1; HRMS (EI) m/z
calcd for C26H23N3O6S, 505.1308; found, 505.1308.
</para>

■ ASSOCIATED CONTENT
*S Supporting Information
Characterization data, X-ray crystallography data (3ab, cif), and
1H, 13C{1H}, and 19F NMR spectra for new compounds. This

Article

material is available free of charge via the Internet at http://
pubs.acs.org.

■ AUTHOR INFORMATION
Corresponding Author
*E-mail: phlee@kangwon.ac.kr.
Notes
The authors declare no competing ﬁnancial interest.

■ ACKNOWLEDGMENTS

This work was supported by the National Research Foundation
of Korea (NRF) grant
funded by the Korea government
(MSIP) (No. 2014001403).

■ REFERENCES

(1) Sato, N. In Comprehensive Heterocyclic Chemistry II; Katritzky, A.
R., Rees, C. W., Boulton, A. J., Eds.; Elsevier: Oxford, 1996.
(2) (a) Urban, S.; Hickford, S. J. H.; Blunt, J. W.; Munro, M. H. G.
Curr. Org. Chem. 2000, 4, 765. (b) Ohta, A.; Aoyagi, Y. Rev. Heteroat.
Chem. 1998, 18, 141. (c) Gohlke, H.; Gundisch, D.; Schwarz, S.; Seitz,
J. Med. Chem. 2002, 45, 1065.
G.; Tilotta, M. C.; Wegge, T.
(d) Cavalier, J. F.; Burton, M.; Dussart, F.; Marchand, F.; Rees, J. F.;
Marchant-Brynaert, J. Bioorg. Med. Chem. 2001, 9, 1037. (e) Fruit, C.;
Turck, A.; Plé, N.; Mojovic, L.; Quéguiner, G. Tetrahedron 2001, 57,
9429. (f) Hirsh, A. J.; Molino, B. F.; Zhang, J.; Astakhova, N.; Geiss,
W. B.; Sargent, B. J.; Swenson, B. D.; Usyatinsky, A.; Wyle, M. J.;
Boucher, R. C.; Smith, R. T.; Zamurs, A.; Johnson, M. R. J. Med. Chem.
2006, 49, 4098. (g) Berkers, C. R.; Leestemaker, Y.; Schuurman, K. G.;
Ruggeri, B.; Jones-Bolin, S.; Williams, M.; Ovaa, H. Mol. Pharmaceutics
2012, 9, 1126. (h) Wu, X.-A.; Zhao, Y.-M.; Yu, N.-J. J. Asian Nat. Prod.
Res. 2007, 9, 437. (i) Duran, R.; Zubia, E.; Ortega, M. J.; Naranjo, S.;
Salva, J. Tetrahedron 1999, 55, 13225.
(3) Büchi, G.; Galindo, J. J. Org. Chem. 1991, 56, 2605.
(4) Aparicio, D.; Attanasi, O. A.; Filippone, P.; Ignacio, R.; Lillini, S.;
Mantellini, F.; Palacios, F.; de los Santos, J. M. J. Org. Chem. 2006, 71,
5897.
(5) Elmssty, T. A.; Castle, L. Org. Lett. 2005, 7, 5529.
(6) Matsushita, H.; Lee, S.-H.; Yoshida, K.; Clapham, B.; Koch, G.;
Zimmermann, J.; Janda, K. D. Org. Lett. 2004, 6, 4627.
(7) Taber, D. F.; DeMatteo, P. W.; Taluskie, K. V. J. Org. Chem.
2007, 72, 1492.
(8) Gnanaprakasam, B.; Balaraman, E.; Ben-David, Y.; Milstein, D.
Angew. Chem., Int. Ed. 2011, 50, 12240.
(9) Palacios, F.; de Retana, A. M. O.; Gil, J. I.; de Munain, R. L. Org.
Lett. 2002, 4, 2405.
(10) (a) Mehta, V. P.; Modha, S. G.; Van der Eycken, E. V. J. Org.
Chem. 2010, 75, 976. (b) Modha, S. G.; Trivedi, J. C.; Mehta, V. P.;
Ermolat’ev, D. S.; Van der Eycken, E. V. J. Org. Chem. 2011, 76, 846.
(c) Mehta, V. P.; Sharma, A.; Van Hecke, K.; Van Meervelt, L.; Van
der Eycken, E. V. J. Org. Chem. 2008, 73, 2382. (d) Mosrin, M.;
Bresser, T.; Knochel, P. Org. Lett. 2009, 11, 3406. (e) Liu, W.; Wise, D.
S.; Townsend, L. B. J. Org. Chem. 2001, 66, 4783. (f) Buron, F.; Plé,
N.; Turck, A.; Queguiner, G. J. Org. Chem. 2005, 70, 2616.
(11) For reviews, see: (a) Davies, H. M. L.; Alford, J. S. Chem. Soc.
Rev. 2014, 43, 5151. (b) Anbarasan, P.; Yadagiri, D.; Rajasekar, S.
Synthesis 2014, 46, 3004 and references therein. (c) Horneff, T.;
Chuprakov, S.; Chernyak, N.; Gevorgyan, V.; Fokin, V. V. J. Am. Chem.
Soc. 2008, 130, 14972. (d) Miura, T.; Yamauchi, M.; Murakami, M.
Chem. Commun. 2009, 1470. (e) Chattopadhyay, B.; Gevorgyan, V.
Org. Lett. 2011, 13, 3746. (f) Shi, Y.; Gevorgyan, V. Org. Lett. 2013, 15,
5394. (g) Miura, T.; Hiraga, K.; Biyajima, T.; Nakamuro, T.;
Murakami, M. Org. Lett. 2013, 15, 3298. (h) Schultz, E. E.; Sarpong,
R. J. Am. Chem. Soc. 2013, 135, 4696. (i) Chuprakov, S.; Kwok, S. W.;
Fokin, V. V. J. Am. Chem. Soc. 2013, 135, 4652. (j) Parr, B. T.; Green,
S. A.; Davies, H. M. L. J. Am. Chem. Soc. 2013, 135, 4716. (k) Zibinsky,
M.; Fokin, V. V. Angew. Chem., Int. Ed. 2013, 52, 1507. (l) Spangler, J.
E.; Davies, H. M. L. J. Am. Chem. Soc. 2013, 135, 6802. (m) Miura, T.;

2382

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

Article

The Journal of Organic Chemistry

Funakoshi, Y.; Murakami, M. J. Am. Chem. Soc. 2014, 136, 2272.
(n) Kwok, S. W.; Zhang, L.; Grimster, N. P.; Fokin, V. V. Angew.
Chem., Int. Ed. 2014, 53, 3452. (o) Zibinsky, M.; Fokin, V. V. Org. Lett.
2011, 13, 4870. (p) Alford, J. S.; Spangler, J. E.; Davies, H. M. L. J. Am.
Chem. Soc. 2013, 135, 11712. (q) Jeon, H. J.; Jung, D. J.; Kim, J. H.;
Kim, Y.; Bouffard, J.; Lee, S.-g. J. Org. Chem. 2014, 79, 9865. (r) Jung,
D. J.; Jeon, H. J.; Kim, J. H.; Kim, Y.; Lee, S.-g. Org. Lett. 2014, 16,
2208. (s) Chattopadhyay, B.; Gevorgyan, V. Angew. Chem., Int. Ed.
2012, 51, 862. (t) Gulevich, A. V.; Gevorgyan, V. Angew. Chem., Int.
Ed. 2013, 52, 1371. (u) Tang, X.-Y.; Zhang, Y.-S.; He, L.; Wei, Y.; Shi,
M. Chem. Commun. 2015, 51, 133. (v) Liu, R.; Zhang, M.; Winston-
McPherson, G.; Tang, W. Chem. Commun. 2013, 49, 4376.
(12) (a) Kim, S.; Mo, J.; Kim, J.; Ryu, T.; Lee, P. H. Asian J. Org.
Chem. 2014, 3, 926. (b) Kim, C.-E.; Park, S.; Eom, D.; Seo, B.; Lee, P.
H. Org. Lett. 2014, 16, 1900. (c) Kim, C.-E.; Park, Y.; Park, S.; Lee, P.
H. Adv. Synth. Catal. 2014, 357, 210. (d) Seo, B.; Jeon, W.; Kim, J.;
Kim, S.; Lee, P. H. J. Org. Chem. 2015, 80, 722.
(13) Park, S.; Yong, W.-S.; Kim, S.; Lee, P. H. Org. Lett. 2014, 16,
4468.
(14) During the preparation of this manuscript, Zhang et al. reported
synthesis of dihydropyrazines
through the Rh-catalyzed trans-
annulation of 1-sulfonyl-1,2,3-triazoles with 2H-azirines: Ding, H.;
Hong, S.; Zhang, N. Tetrahedron Lett. 2015, 56, 507. After submission
of this paper, Park et al. reported synthesis of unsymmetrical pyrazines
based on α-diazo oximine ethers: Loy, N. S.; Kim, S.; Park, C.-M. Org.
Lett. 2015, DOI: 10.1021/ol5034173.
(15) (a) Yoo, E. J.; Ahlquist, M.; Kim, S. H.; Bae, I.; Fokin, V. V.;
Sharpless, K. B.; Chang, S. Angew. Chem., Int. Ed. 2007, 46, 1730.
(b) Raushel, J.; Fokin, V. V. Org. Lett. 2010, 12, 4952. (c) Liu, Y.;
Wang, X.; Xu, J.; Zhang, Q.; Zhao, Y.; Hu, Y. Tetrahedron 2011, 67,
6294.
(16) (a) Wei, Y. J.; Chan, W. C.; Park, C.-M. J. Am. Chem. Soc. 2012,
134, 4104. (b) Qi, X.; Xu, X.; Park, C.-M. Chem. Commun. 2012, 48,
3996. (c) Loy, N. S. Y.; Singh, A.; Xu, X.; Park, C.-M. Angew. Chem.,
Int. Ed. 2013, 53, 2212.
(17) CCDC 1037286 (3ab) contains the supplementary crystallo-
graphic data for this paper. These data can be obtained free of charge
from The Cambridge Crystallographic Data Center via www.ccdc.cam.
ac.uk/data_request/cif.
(18) In reference 14, authors suggested an intramolecular hydrogen
transfer mechanism.

2383

DOI: 10.1021/acs.joc.5b00036
J. Org. Chem. 2015, 80, 2376−2383

